Stroke Treatment Academic Industry Roundtable (STAIR) Recommendations for Maximizing the Use of Intravenous Thrombolytics and Expanding Treatment Options With Intra-arterial and Neuroprotective Therapies

被引:202
作者
Albers, Gregory W. [1 ]
Goldstein, Larry B. [2 ]
Hess, David C. [3 ]
Wechsler, Lawrence R. [4 ]
Furie, Karen L. [5 ]
Gorelick, Philip B. [6 ]
Hurn, Patty [7 ]
Liebeskind, David S. [8 ]
Nogueira, Raul G. [9 ]
Saver, Jeffrey L. [8 ]
机构
[1] Stanford Univ, Dept Neurol & Neurol Sci, Stanford Stroke Ctr, Palo Alto, CA 94304 USA
[2] Duke Univ, Med Ctr, Durham, NC USA
[3] Med Coll Georgia, Augusta, GA 30912 USA
[4] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[5] Massachusetts Gen Hosp, Boston, MA 02114 USA
[6] Univ Illinois, Coll Med, Chicago, IL USA
[7] Univ Texas Syst, Austin, TX USA
[8] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA
[9] Emory Univ, Sch Med, Atlanta, GA USA
关键词
acute stroke; basic science; drug trials; neuroprotection; thrombolysis; ACUTE ISCHEMIC-STROKE; TISSUE-PLASMINOGEN ACTIVATOR; TIME; REVASCULARIZATION; TRIALS; MILD; ASSOCIATION; ALTEPLASE; PENUMBRA; OUTCOMES;
D O I
10.1161/STROKEAHA.111.618850
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose-The goal of the Stroke Treatment Academic Industry Roundtable (STAIR) meetings is to advance the development of acute and restorative stroke therapies. Summary of Review-At the STAIR VII recommendations for strategies to maximize the use of intravenous thrombolytics through targeting public education, and the refinement of current treatment exclusion criteria were proposed. Increased utilization of mechanical devices for intra-arterial recanalization can be achieved by obtaining more definitive evidence of efficacy in randomized clinical trials, identification of patient characteristics associated with treatment efficacy, optimization of technical approaches, clarification of effective time windows, and development of approaches to limit complications. Neuroprotective strategies remain viable; recommendations for further study of these agents include an emphasis on rapid administration, consideration of the systemic effects of ischemic stroke, prevention of complications associated with early reperfusion, a focus on agents with multiple mechanisms of action, and consideration of possible interactions between neuroprotective and thrombolytic therapies. Conclusions-Extending intravenous thrombolysis to a broader patient population, clarifying the risk and benefits of intra-arterial reperfusion therapies, and further development of neuroprotective therapies were the key recommendations from STAIR VII. (Stroke. 2011;42:2645-2650.)
引用
收藏
页码:2645 / 2650
页数:6
相关论文
共 41 条
[21]   Revascularization end points in stroke interventional trials - Recanalization versus reperfusion in IMS-I [J].
Khatri, P ;
Neff, J ;
Broderick, JP ;
Khoury, JC ;
Carrozzella, J ;
Tomsick, T .
STROKE, 2005, 36 (11) :2400-2403
[22]   Good clinical outcome after ischemic stroke with successful revascularization is time-dependent [J].
Khatri, P. ;
Abruzzo, T. ;
Yeatts, S. D. ;
Nichols, C. ;
Broderick, J. P. ;
Tomsick, T. A. .
NEUROLOGY, 2009, 73 (13) :1066-1072
[23]   Intracranial hemorrhage associated with revascularization therapies [J].
Khatri, Pooja ;
Wechsler, Lawrence R. ;
Broderick, Joseph P. .
STROKE, 2007, 38 (02) :431-440
[24]   Evolving paradigms in imaging the ischemic penumbra with multimodal magnetic resonance imaging [J].
Kidwell, CS ;
Alger, JR ;
Saver, JL .
STROKE, 2003, 34 (11) :2729-2735
[25]   National US estimates of recombinant tissue plasminogen activator use - ICD-9 codes substantially underestimate [J].
Kleindorfer, Dawn ;
Lindsell, Christopher J. ;
Brass, Lawrence ;
Koroshetz, Walter ;
Broderick, Joseph P. .
STROKE, 2008, 39 (03) :924-928
[26]  
Kumar N, 2010, DIABETES CARE, V33, P2531, DOI [10.2337/dc10-1125, 10.2337/dc10.1125]
[27]   The Penumbra Pivotal Stroke Trial Safety and Effectiveness of a New Generation of Mechanical Devices for Clot Removal in Intracranial Large Vessel Occlusive Disease [J].
Langer, David ;
Alexander, Michael ;
Janardhan, Vallabh ;
Hartmann, Marius ;
Jansen, Olav ;
Sit, Siu Po ;
Yavagal, Dileep ;
Stingele, Robert ;
DeMuth, George ;
Bose, Arani ;
Clark, Wayne ;
Lutsep, Helmi ;
Barnwell, Stanley ;
Nesbit, Gary ;
Egan, Robert ;
North, Elizabeth ;
Yanase, Lisa ;
Lowenkopf, Ted ;
Petersen, Bryan ;
Grunwald, Iris Quasar ;
Mayer, Thomas ;
Doerfler, Arnd ;
Struffert, Tobias ;
Engelhorn, Tobias ;
Richter, Gregor ;
Grunwald, Iris Quasar ;
Reith, Wolfgang ;
Berkefeld, Joachim ;
Madison, Michael ;
Myers, Mark ;
Goddard, James ;
Lassig, Jeffrey ;
Lopes, Demetrius ;
Shownkeen, Harish ;
Echiverri, Henry ;
Nour, Fred ;
Mazumdar, Avi ;
Budzik, Ronald ;
Pema, Peter ;
Frei, Don ;
Huddle, Daniel ;
Bellon, Richard ;
Heck, Donald ;
Ferguson, Robert ;
McDougall, Cameron ;
Flaster, Murray ;
Frey, James ;
Albuquerque, Felipe ;
Malkoff, Marc ;
Zaidat, Osama .
STROKE, 2009, 40 (08) :2761-2768
[28]   Hemorrhagic transformation in acute ischemic stroke - Potential contributing factors in the European Cooperative Acute Stroke Study [J].
Larrue, V ;
vonKummer, R ;
delZoppo, G ;
Bluhmki, E .
STROKE, 1997, 28 (05) :957-960
[29]   Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials [J].
Lees, Kennedy R. ;
Bluhmki, Erich ;
von Kummer, Ruediger ;
Brott, Thomas G. ;
Toni, Danilo ;
Grotta, James C. ;
Albers, Gregory W. ;
Kaste, Markku ;
Marler, John R. ;
Hamilton, Scott A. ;
Tilley, Barbara C. ;
Davis, Stephen M. ;
Donnan, Geoffrey A. ;
Hacke, Werner ;
Ninds, Ecass Atlantis .
LANCET, 2010, 375 (9727) :1695-1703
[30]   Hospital Arrival Time and Intravenous t-PA Use in US Academic Medical Centers, 2001-2004 [J].
Lichtman, Judith H. ;
Watanabe, Emi ;
Allen, Norrina B. ;
Jones, Sara B. ;
Dostal, Jackie ;
Goldstein, Larry B. .
STROKE, 2009, 40 (12) :3845-3850